Amryt has paved its way for marketing for Lojuxta by signing a deal with with GryNumber Health. The exclusive distribution agreement will cover Central and Eastern Europe (CEE), as GryNumber is one of the leading healthcare consultancy and distribution companies in the region.
According to the announcement issued by Amryt on Wednesday, the agreement covers the distribution of Lojuxta across Austria, Croatia, Czech Republic, Estonia, Finland, Hungary, Latvia, Lithuania, Poland, Slovakia and Slovenia.
Lojuxta is a treatment for the rare, life-threatening, genetic cholesterol disorder Homozygous Familial Hypercholesterolemia (HoFH) and Amryt estimates that there are approximately 100 patients with HoFH in these countries, with requests for access to Lojuxta made by clinicians throughout the region.
Amryt has signed distribution contracts covering Saudi Arabia and Switzerland recently as it continues to develop sales of Lojuxta, having acquired exclusive marketing rights to the drug across certain territories in December 2016.
Dr. Joe Wiley, Chief Executive Officer of Amryt Pharma, said that GryNumber Health has a well-established presence in the healthcare markets in Central and Eastern Europe and therefore is an ideal partner for us in the region. “We are delighted to have signed this exclusive distribution agreement as we look to provide access to Lojuxta to patients suffering from HoFH across our licensed territories,” he said.